Imago BioSciences, Inc. Net Income
Imago BioSciences, Inc. reported Net Income of -$16.78 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2022-11-09
- Imago BioSciences, Inc. net income (loss) attributable to parent for the quarter ending 2022-09-30 was -$16.78M.
- Imago BioSciences, Inc. net income (loss) attributable to parent for the quarter ending 2022-06-30 was -$13.74M.
- Imago BioSciences, Inc. net income (loss) attributable to parent for the quarter ending 2022-03-31 was -$16.39M.
- Imago BioSciences, Inc. net income (loss) attributable to parent for the quarter ending 2021-12-31 was -$14.73M.
- Imago BioSciences, Inc. net income (loss) attributable to parent for fiscal 2021 was -$42.31M.
- Imago BioSciences, Inc. net income (loss) attributable to parent for fiscal 2020 was -$17.83M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$16.78M 10-Q · filed 2022-11-09 | -$30.52M derived: sum of 2 quarters · filed 2022-11-09 | -$46.91M 10-Q · filed 2022-11-09 | -$61.64M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | -$13.74M 10-Q · filed 2022-11-09 | -$30.14M 10-Q · filed 2022-08-12 | -$44.86M derived: sum of 3 quarters · filed 2022-11-09 | -$56.53M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | -$16.39M 10-Q · filed 2022-11-09 | -$31.12M derived: sum of 2 quarters · filed 2022-11-09 | -$42.79M derived: sum of 3 quarters · filed 2022-11-09 | -$51.60M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | -$14.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$26.40M derived: sum of 2 quarters · filed 2022-11-09 | -$35.20M derived: sum of 3 quarters · filed 2022-11-09 | -$42.31M 10-K · filed 2022-03-24 |
| 2021-09-30 | -$11.67M 10-Q · filed 2022-11-09 | -$20.48M derived: sum of 2 quarters · filed 2022-11-09 | -$27.59M 10-Q · filed 2022-11-09 | -$33.13M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$8.81M 10-Q · filed 2022-11-09 | -$15.91M 10-Q · filed 2022-08-12 | -$21.46M derived: sum of 3 quarters · filed 2022-11-09 | -$25.77M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-03-31 | -$7.11M 10-Q · filed 2022-11-09 | -$12.66M derived: sum of 2 quarters · filed 2022-11-09 | -$16.97M derived: sum of 3 quarters · filed 2022-11-09 | -$20.70M derived: sum of 4 quarters · filed 2022-11-09 |
| 2020-12-31 | -$5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$9.86M derived: sum of 2 quarters · filed 2022-03-24 | -$13.59M derived: sum of 3 quarters · filed 2022-03-24 | -$17.83M 10-K · filed 2022-03-24 |
| 2020-09-30 | -$4.31M 10-Q · filed 2021-11-10 | -$8.04M derived: sum of 2 quarters · filed 2021-11-10 | -$12.28M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$3.73M 10-Q · filed 2021-11-10 | -$7.97M 10-Q · filed 2021-08-19 | ||
| 2020-03-31 | -$4.25M 10-Q · filed 2021-11-10 |